Sleep Disorders (September)

Date of Issue: 09/01/2015 | Volume: 13 | Number: 9

Issue Links:Learning Objectives | Editorial Information

Robert Rosenberg is one of the country’s premier sleep disorders experts, and in this month’s Q&A, he tells us what all psychiatrists need to know (and do) about sleep disorders. We also provide you with a primer on the diagnosis and treatment of narcolepsy, and we evaluate the newly approved drug, Xyrem.

In This Issue


A Narcolepsy Primer, With a Focus on Xyrem

Topics: Psychopharmacology Tips | Sleep Disorders

Narcolepsy affects about 1 out of 2000 people, for a prevalence rate of 0.05%. This puts it officially in the category of rare diseases. So why are we asking you to read about such a rare disorder? Partly because there’s a lot of comorbidity between narcolepsy and most psychiatric disorders. And partly because Jazz Pharmaceuticals is placing lots of ads in psychiatric journals urging us to diagnose more narcolepsy so that we’ll use their new drug Xyrem.

Read More
Expert Q&A

What Psychiatrists Should Know About Sleep Medicine

Topics: Benzodiazepines | Practice Tools and Tips | Psychopharmacology Tips | Sleep Disorders

What are some of the basic questions that we should be asking our patients who complain of sleep problems? TCPR talks to Robert S. Rosenberg, DO, FCCP to get his insight on sleep disorders, sleep apnea, restless leg syndrome, sleep studies, and benzodiazepines.

Read More
Research Update

Should We Add Stimulants to SSRIs to Treat Geriatric Depression?

Topics: Depressive Disorder | Psychopharmacology Tips | Research Updates

Geriatric depression often presents with apathy, low energy and motivation, and cognitive decline, so theoretically stimulants are a natural choice. Past studies of combining stimulants with antidepressants have been mainly small open trials, with mostly positive results. But we haven’t seen the kind of rigorous double-blind methodology we’d like. A new study fills that gap.

Read More
News of Note

Rexulti for Schizophrenia and MDD: Is It Abilify, Round 2?

Topics: Antidepressants | Depressive Disorder | News of Note

On July 10, the U.S. Food and Drug Administration (FDA) approved Otsuka and Lundbeck’s Rexulti (brexpiprazole) for schizophrenia and as an add-on to antidepressants for adults with depression. As the name suggests, it’s chemically and structurally related to aripiprazole (Abilify).

Read More